HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma

Heidi Koskela; Yilin Li; Titta Joutsiniemi; Taru Muranen; Veli Matti Isoviita; Kaisa Huhtinen; Giulia Micoli; Kari Lavikka; Giovanni Marchi; Sakari Hietanen; Anni Virtanen; Sampsa Hautaniemi; Jaana Oikkonen; Johanna Hynninen

doi:10.1016/j.ygyno.2023.11.027

HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma

Heidi Koskela, Yilin Li, Titta Joutsiniemi, Taru Muranen, Veli Matti Isoviita, Kaisa Huhtinen, Giulia Micoli, Kari Lavikka, Giovanni Marchi, Sakari Hietanen, Anni Virtanen, Sampsa Hautaniemi, Jaana Oikkonen, Johanna Hynninen

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Originalspråk	engelska
Tidskrift	Gynecologic Oncology
Volym	180
Sidor (från-till)	91-98
Antal sidor	8
ISSN	0090-8258
DOI	https://doi.org/10.1016/j.ygyno.2023.11.027
Status	Publicerad - jan. 2024
MoE-publikationstyp	A1 Tidskriftsartikel-refererad

Bibliografisk information

Publisher Copyright:
© 2023 The Authors

Vetenskapsgrenar

3122 Cancersjukdomar
3123 Kvinno- och barnsjukdomar

Åtkomst av dokument

10.1016/j.ygyno.2023.11.027

1-s2.0-S0090825823015706-mainSlutlig publicerad version, 926 KBLicens: CC BY

Citera det här

Koskela, H., Li, Y., Joutsiniemi, T., Muranen, T., Isoviita, V. M., Huhtinen, K., Micoli, G., Lavikka, K., Marchi, G., Hietanen, S., Virtanen, A., Hautaniemi, S., Oikkonen, J., & Hynninen, J. (2024). HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma. Gynecologic Oncology, 180, 91-98. https://doi.org/10.1016/j.ygyno.2023.11.027

@article{2924002f5eaa47648e4fbb714a9e7f63,

title = "HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma",

keywords = "Genetic testing, High-grade serous ovarian cancer (HGSC), Homologous-recombination-deficiency (HRD), Platinum, Whole-genome-sequencing (WGS), 3122 Cancers, 3123 Gynaecology and paediatrics",

author = "Heidi Koskela and Yilin Li and Titta Joutsiniemi and Taru Muranen and Isoviita, {Veli Matti} and Kaisa Huhtinen and Giulia Micoli and Kari Lavikka and Giovanni Marchi and Sakari Hietanen and Anni Virtanen and Sampsa Hautaniemi and Jaana Oikkonen and Johanna Hynninen",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2024",

month = jan,

doi = "10.1016/j.ygyno.2023.11.027",

language = "English",

volume = "180",

pages = "91--98",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

}

Koskela, H, Li, Y, Joutsiniemi, T, Muranen, T , Isoviita, VM, Huhtinen, K, Micoli, G , Lavikka, K , Marchi, G, Hietanen, S, Virtanen, A , Hautaniemi, S , Oikkonen, J & Hynninen, J 2024, 'HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma', Gynecologic Oncology, vol. 180, s. 91-98. https://doi.org/10.1016/j.ygyno.2023.11.027

TY - JOUR

T1 - HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma

AU - Koskela, Heidi

AU - Li, Yilin

AU - Joutsiniemi, Titta

AU - Muranen, Taru

AU - Isoviita, Veli Matti

AU - Huhtinen, Kaisa

AU - Micoli, Giulia

AU - Lavikka, Kari

AU - Marchi, Giovanni

AU - Hietanen, Sakari

AU - Virtanen, Anni

AU - Hautaniemi, Sampsa

AU - Oikkonen, Jaana

AU - Hynninen, Johanna

PY - 2024/1

Y1 - 2024/1

KW - Genetic testing

KW - High-grade serous ovarian cancer (HGSC)

KW - Homologous-recombination-deficiency (HRD)

KW - Platinum

KW - Whole-genome-sequencing (WGS)

KW - 3122 Cancers

KW - 3123 Gynaecology and paediatrics

U2 - 10.1016/j.ygyno.2023.11.027

DO - 10.1016/j.ygyno.2023.11.027

M3 - Article

AN - SCOPUS:85179119032

SN - 0090-8258

VL - 180

SP - 91

EP - 98

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -